### ü´† Heart Failure: Left Ventricular Dysfunction on Point-of-Care Ultrasound

#### ‚úÖ True Statements
1. **Heart failure with reduced ejection fraction (HFrEF)** is suggested by a **dilated, rounded left ventricle** with **minimal systolic size reduction** on point-of-care ultrasound.
2. A **lack of interventricular septal thickening during systole** is a specific finding indicating **severely reduced left ventricular function**.
3. A **posterior wall that thickens normally during systole**, when the **interventricular septum does not**, supports the diagnosis of **systolic dysfunction**.
4. On parasternal long-axis view, a **diastolic mitral valve anterior leaflet-to-septum distance >1 cm** suggests **severe reduction in left ventricular function**.
5. The **absence of pericardial effusion** on ultrasound makes **cardiac tamponade** unlikely in the setting of hypotension or shock.
6. **Normal opening of the aortic and mitral valve leaflets** on ultrasound rules out **significant valvular stenosis**.

#### üí¨ Extra
1. The parasternal long-axis view allows qualitative visual estimation of ejection fraction and gross chamber size.
2. Normal interventricular septal motion and thickening contribute to systolic function; their absence is pathologic.
4. The anterior mitral valve leaflet moves closer to the septum in early diastole; poor movement reflects poor LV filling and function.

#### üî∑ Tags
#Cardiology #HeartFailure #HFrEF #Ultrasound #HospitalCare #EmergentCare #PatientOver65

#### üìô Reference
MKSAP 19, Cardiovascular Medicine, Evaluation of Heart Failure with Point-of-Care Ultrasound.

#### üÜî Question ID
CVVDX24044

#### üïí Last Updated
January 2025

---

#### üñºÔ∏è Supplemental Figure

<figure>
  <img src="TTE Heart failure with reduced ejection fraction.jpg" alt="Parasternal long-axis view of the left ventricle on point-of-care ultrasound">
  <figcaption>
    Parasternal long-axis ultrasound image demonstrating a dilated, rounded **left ventricle (LV)** with poor systolic contraction, consistent with **heart failure with reduced ejection fraction (HFrEF)**. Other labeled structures include the **aortic valve (AV)**, **interventricular septum (IVS)**, **left atrium (LA)**, and **mitral valve (MV)**.
  </figcaption>
</figure>

#### üîä Supplemental Video

<figure>
  <video controls src="Heart failure with reduced ejection fraction.mp4"></video>
  <figcaption>
    Point-of-care transthoracic echocardiography in the parasternal long-axis view showing **severely reduced left ventricular ejection fraction**, as evidenced by minimal inward motion of the **LV walls** during systole and increased **anterior mitral valve leaflet-to-septum distance**.
  </figcaption>
</figure>

---

#### üìñ Related Text
MKSAP 19: Cardiovascular Medicine ‚Äî Heart Failure > Diagnosis and Evaluation of Heart Failure

---

### üìò Related Text Derivations

#### ‚úÖ True Statements
1. Initial diagnostic testing for **heart failure** includes **electrocardiogram (ECG)**, **chest radiography**, and **laboratory studies**.
2. An **ECG** may reveal evidence of **myocardial infarction**, **tachyarrhythmia**, or **left ventricular hypertrophy (LVH)** in patients with suspected **heart failure**.
3. **Chest radiography** findings that support a diagnosis of **heart failure** include **cardiomegaly**, **vascular congestion**, **Kerley B lines**, and **pleural effusion**.
4. In patients with **dyspnea of unknown etiology**, **brain natriuretic peptide (BNP)** or **N-terminal pro‚ÄìB-type natriuretic peptide (NT-proBNP)** levels help distinguish **cardiac** from **pulmonary** causes.
5. **BNP levels >400 pg/mL (400 ng/L)** are suggestive of **heart failure**, while levels **<100 pg/mL (100 ng/L)** make heart failure unlikely.
6. **BNP levels between 100 and 400 pg/mL** are **not sensitive or specific** for diagnosing or excluding **heart failure**.
7. Elevated **BNP levels** may occur in **kidney disease**, **older age**, **sepsis**, **female sex**, and with use of **angiotensin receptor‚Äìneprilysin inhibitors (ARNIs)**.
8. **Obesity** is associated with **lower BNP levels**, potentially confounding heart failure diagnosis.
9. For **NT-proBNP**, levels <300 pg/mL make **heart failure very unlikely**.
10. **Age-specific thresholds** for NT-proBNP indicating **high likelihood of heart failure** are: >450 pg/mL for age <50, >900 pg/mL for age 50‚Äì75, and >1800 pg/mL for age >75.
11. Laboratory evaluation of **heart failure** should include **complete blood count**, **electrolytes**, **kidney function**, **glucose**, **lipids**, **liver chemistries**, **iron studies**, and **thyroid-stimulating hormone (TSH)**.
12. **TSH testing** is used to identify **hypothyroidism** or **hyperthyroidism** as reversible causes of **heart failure**.
13. **Iron studies** are used to evaluate for **hemochromatosis** in patients with **heart failure**.
14. **Echocardiography** is the **primary diagnostic test** for evaluating **heart failure**, providing data on **chamber size**, **wall thickness**, **systolic and diastolic function**, and **valvular disease**.
15. **Regional wall motion abnormalities** on echocardiography suggest **coronary artery disease (CAD)** as a cause of **heart failure**.
16. **Left ventricular hypertrophy** on echocardiography may suggest **hypertension** or **cardiac amyloidosis**.
17. **Cardiac magnetic resonance (CMR) imaging** is used to evaluate **myocarditis**, **infiltrative cardiomyopathies**, and **hypertrophic cardiomyopathy** in the setting of **heart failure**.
18. **Routine CMR imaging** is **not recommended** unless **echocardiographic images are inadequate** or **a specific diagnosis is suspected**.
19. The diagnosis of **HFrEF**, **HFmrEF**, and **HFpEF** is based on **measured ejection fraction** and **evidence of increased left ventricular (LV) filling pressures**.
20. **Elevated LV filling pressures** may be identified by **high central venous pressure**, **elevated BNP/NT-proBNP**, **echocardiographic criteria**, or **invasive hemodynamic measurements**.

#### üí¨ Extra
4. BNP and NT-proBNP are natriuretic peptides released in response to increased ventricular wall stretch and filling pressures.
7. ARNI therapy increases BNP levels by inhibiting neprilysin, which normally degrades BNP.
8. Adipose tissue clears natriuretic peptides more efficiently, contributing to low levels in obesity.
10. NT-proBNP thresholds reflect age-dependent baseline changes in natriuretic peptide metabolism.
14. Echocardiography is the most accessible and informative initial test in heart failure assessment.
17. CMR can help differentiate between ischemic and nonischemic cardiomyopathies based on tissue characterization.
19. Ejection fraction classification distinguishes systolic (HFrEF) from mid-range (HFmrEF) and preserved (HFpEF) heart failure subtypes.

#### üî∑ Tags
#HeartFailure #HFrEF #HFpEF #BNP #NTproBNP #Echocardiography #CMR #Diagnosis #HospitalCare

---

#### üñºÔ∏è Supplemental Figure

<figure>
  <img src="CXR Decompensated Heart Failure.jpg" alt="Chest Radiograph Showing Decompensated Heart Failure">
  <figcaption>
    <strong>Chest Radiograph Showing Evidence of Decompensated Heart Failure</strong><br>
    Chest radiograph showing evidence of decompensated heart failure with pulmonary edema characterized by diffuse increased interstitial opacities, including Kerley B lines; prominent and indistinct pulmonary vasculature; and tiny pleural effusions.
  </figcaption>
</figure>

#### üñºÔ∏è Supplemental Table

<table>
  <caption><strong>Other Causes of Heart Failure and Clinical Markers</strong></caption>
  <thead>
    <tr>
      <th>Cause</th>
      <th>Clinical Markers</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Cardiotoxins</td>
      <td>
        Clinical history of cancer treated with chemotherapy<br>
        Treatment with hydroxychloroquine, stimulants for ADHD
      </td>
    </tr>
    <tr>
      <td>Rheumatologic</td>
      <td>History</td>
    </tr>
    <tr>
      <td>Familial</td>
      <td>History: at least three generations</td>
    </tr>
    <tr>
      <td>Infectious</td>
      <td>History of HIV, COVID-19, Chagas disease</td>
    </tr>
    <tr>
      <td>Tachycardia</td>
      <td>
        Either supraventricular (atrial arrhythmia with persistent tachycardia) or PVC mediated<br>
        (&gt;10% ectopic beats on ambulatory ECG)
      </td>
    </tr>
    <tr>
      <td>Amyloid</td>
      <td>LVH on echo with low voltage on ECG, neuropathy, carpal tunnel syndrome</td>
    </tr>
    <tr>
      <td>Other infiltrative</td>
      <td>
        Clinical suggestions for hemochromatosis (new-onset diabetes, skin bronzing),<br>
        sarcoid (AV block, arrhythmias, lymphadenopathy)
      </td>
    </tr>
    <tr>
      <td>Peripartum</td>
      <td>History</td>
    </tr>
    <tr>
      <td>Stress cardiomyopathy</td>
      <td>History of emotionally or physically stressful event (high catecholamine state)</td>
    </tr>
    <tr>
      <td>Substance use</td>
      <td>History of alcohol, cocaine, methamphetamine use</td>
    </tr>
    <tr>
      <td>Autoimmune</td>
      <td>Patients with cancer who are receiving immune checkpoint inhibitors such as pembrolizumab</td>
    </tr>
  </tbody>
</table>

<p><em>ADHD = attention-deficit/hyperactivity disorder; AV = atrioventricular; LVH = left ventricular hypertrophy; PVC = premature ventricular contraction.</em></p>
